Cycle and repair proteins are measured as states: a kinase active or inhibited, a licensing factor present in one phase and destroyed in another, a damage mark that appears after an insult. Abundance on its own usually reports the culture's phase distribution rather than the treatment, which is why the control and the sample matter more here than the clone.
A geminin antibody and a gh2ax antibody on licensing and damage
Geminin is present from S phase to mitosis and destroyed at the exit, which makes it a proliferation marker whose absence in a tissue means quiescence rather than a failed stain, and it pairs with a licensing factor for the standard cycling readout. Phosphorylated histone H2AX marks double strand breaks within minutes, so the informative experiment is an irradiated or drug-treated sample at a documented time, read as foci per nucleus rather than as a band, with an untreated baseline that is never zero.
An atm antibody and a blm antibody on the damage response
The apical kinase is read by its own autophosphorylation and by the phosphorylation of its substrates, so the reagent set is a phospho clone plus a total antibody and a treated positive control. The helicase is read by localisation to damage or to fragile sites, which is an imaging experiment with a colocalisation control rather than a blot. Both are large nuclear proteins, so nuclear extraction and gentle lysis matter, and a whole cell lysate usually reports nothing.
An mlh1 antibody and an idh1 antibody as clinical-shaped markers
Mismatch repair proteins are read in tissue as retained or lost, which is a binary with real consequences, so the clone needs a documented pattern, an internal positive control in the section and careful retrieval, because weak retrieval reads as loss. The metabolic enzyme is read for a specific mutant form in some tumours, and a mutation-specific clone is a different product from one detecting the wild type protein, which is exactly the distinction a datasheet has to make.
A bim antibody and a trf2 antibody on apoptosis and telomeres
The apoptosis regulator exists as several splice isoforms with different potency, so a blot that shows one band where the literature shows three is a clone that sees one isoform, and a treated positive control is what shows the antibody can see the induced protein. The telomere binding factor is interesting as foci at chromosome ends, which makes immunofluorescence with a telomere probe the informative readout, and its abundance on a blot says little about telomere protection.
Synchronisation, or measuring per cell instead
Where abundance follows the cycle, two designs are honest: synchronise and sample a time course with a phase marker beside the target, or measure per cell by flow cytometry or imaging against DNA content so the phase distribution is part of the result. Comparing two asynchronous populations by blot conflates expression with proliferation rate, which is the commonest error in this literature and the easiest to avoid at the design stage.
Phospho readouts and the buffer they demand
Every kinase and damage signal in this class is read as a modification, so the lysis buffer carries phosphatase and kinase inhibitors from the first second, the sample stays cold, and the total protein is run on the same membrane so a ratio rather than a band is reported. A phosphatase-treated control lane that loses the signal is the cheapest specificity evidence available, and it belongs in the first experiment with a new clone rather than in a revision.
Drug response, and what the antibody has to show
For a cycle inhibitor the antibody set has to demonstrate the pathway rather than the compound: the direct substrate's phosphorylation falls, a downstream marker follows, an unrelated pathway does not move, and the cycle distribution changes as expected. Dose and time both belong on the figure. For repair inhibitors the same logic applies with damage markers, where an untreated arm and a damage-only arm are needed before a combination means anything.
What to ask for before ordering
Ask for genetic validation in your application, the immunogen's position so isoform coverage is predictable, and the exact treatment behind the vendor's own figure with the time point, so the positive control can be reproduced on day one. For a mutation-specific or phospho-specific clone, ask for the residue and the surrounding sequence, since clones from two suppliers against the same site can differ in cross reactivity with a related protein's identical motif.
Questions people ask about cdk4 antibody
Why does abundance not report a treatment?
Because these proteins follow the cycle. Synchronise with a phase marker, or measure per cell against DNA content.
What makes a damage marker readable?
A treated positive control at a documented time, an untreated baseline that is never zero, and foci counted per nucleus rather than a band.
Is a mutation-specific clone the same product?
No. A clone detecting a mutant form is separate from one detecting the wild type protein, and the datasheet has to say which.